INS and metabolic dysfunction-associated steatotic liver disease: Although insulin resistance plays an important role in the pathogenesis of MASLD, metformin failed to prove beneficial effects on the MASLD progression, in contrast with the other category of insulin sensitizers, thiazolidinediones, which in RCTs have shown improvement in steatohepatitis while delaying the progression of liver fibrosis.